Consequently, it inhibits the assembly of stress granules and activates the receptor for the activated C kinase 1 (RACK1)/MAP three kinase 1 (MTK1) apoptosis signaling pathway [17], thereby inhibiting triple-negative breast cancer (TNBC) tumor growth and reducing the resistance of TNBC cells to doxorubicin. This evidence concerns the gene RACK1 and triple-negative breast carcinoma.